Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or
“Novo”), pioneering a holistic approach to patient-first health and
wellness through a multidisciplinary healthcare ecosystem of
services and product innovation, today announced the signing of a
memorandum of understanding with Boditech Med, a global
point-of-care testing leader (“Boditech”), for a marketing and
distribution partnership for the launch and deployment of Boditech
Med’s in-vitro diagnostic solutions and technology in North
America.
Founded in South Korea in 1998, Boditech markets and sells more
than 90 biomarker products in 120 countries. Boditech offers highly
reliable in-vitro diagnostic solutions that empower clinicians and
patients to improve health through quick and reliable tests,
available anywhere and anytime. Along with venous blood and plasma
testing, Boditech's product line includes technologies that enable
accurate, thorough capillary blood tests, based on a small amount
of blood from a finger prick. Boditech also produces COVID-19
antibody and over-the-counter rapid antigen tests.
Boditech recently announced plans to open a manufacturing site
in Miami, Florida and is currently seeking approvals from the U.S.
Food and Drug Administration for several diagnostic solutions in
cardiac, cancer, hormone, infectious disease, and other therapeutic
areas. Boditech intends to bring lower-cost, rapid testing that
covers many critical areas of medicine, from cardiac health to
cancer, to North America.
Robert Mattacchione, Novo’s CEO and Board Chairman, commented,
“On March 23, 2022, Novo announced it had entered into a purchase
agreement to acquire Clinical Consultants International LLC
(“CCI”), a global consulting firm specializing in providing
value-added services for multiple sectors of the medical industry.
One of the many benefits CCI offers Novo is CCI’s portfolio of
leading multi-national healthcare clients, assisting each through
clinical and regulatory development as well as entrance into new
markets. Boditech is one such CCI client. I want to thank both Dr.
Joseph Chalil, for his many years of leadership of CCI and for
introducing Boditech to Novo, along with Eui-Yul Choi, Boditech’s
co-founder and CEO, for selecting Novo to provide Boditech with the
ecosystem and the platform to quickly and efficiently market and
distribute Boditech’s in-vitro diagnostic solutions in North
America. With Boditech’s planned expansion into North America,
together we will improve the health and safety of patients and the
effectiveness and workflow of clinicians.”
Dr. Choi stated, “Diagnostic testing in North America remains a
critical issue for patients, many times taking up to an astounding
three days to get test results. Our proven technology is more cost
effective with actionable results in as little as 12 to 15 minutes.
We recently announced our intention to establish manufacturing
capabilities in Miami, Florida and today are pleased to have
identified our marketing and distribution partner, Novo Integrated
Sciences, for the deployment of our technology in North
America.”
About Boditech Med
Boditech Med is a global leader in point-of-care testing with a
decades-long track record of improving health and quality of life
through innovative in-vitro diagnostic solutions. Since its launch
in 1998, Boditech has developed 85 biomarkers, which support
capillary blood, venous blood, and plasma testing, to meet
customers' evolving needs. Listed as a public company on the
KOSDAQ, Boditech's products aid patients and clinicians in 120
countries.
Learn more about Boditech Med and how its in-vitro diagnostic
are improving health worldwide, please visit
https://www.boditech.co.kr/en
About Novo Integrated Sciences,
Inc.
Novo Integrated Sciences, Inc. is pioneering a holistic approach
to patient-first health and wellness through a multidisciplinary
healthcare ecosystem of multiple patient and consumer touchpoints
for services and product innovation. Novo offers an essential and
differentiated solution to deliver, or intend to deliver, these
services and products through the integration of medical
technology, diagnostic and therapeutic solutions, and
rehabilitative science.
We believe that “decentralizing” healthcare, through the
integration of medical technology and interconnectivity, is an
essential solution to the rapidly evolving fundamental
transformation of how non-catastrophic healthcare is delivered both
now and in the future. Specific to non-critical care, ongoing
advancements in both medical technology and inter-connectivity are
allowing for a shift of the patient/practitioner relationship to
the patient’s home and away from on-site visits to primary medical
centers with mass-services. This acceleration of “ease-of-access”
in the patient/practitioner interaction for non-critical care
diagnosis and subsequent treatment minimizes the degradation of
non-critical health conditions to critical conditions as well as
allowing for more cost-effective healthcare distribution.
The Company’s decentralized healthcare business model is
centered on three primary pillars to best support the
transformation of non-catastrophic healthcare delivery to patients
and consumers:
- First Pillar: Service Networks. Deliver multidisciplinary
primary care services through (i) an affiliate network of clinic
facilities, (ii) small and micro footprint sized clinic facilities
primarily located within the footprint of box-store commercial
enterprises, (iii) clinic facilities operated through a franchise
relationship with the Company, and (iv) corporate operated clinic
facilities.
- Second Pillar: Technology. Develop, deploy, and integrate
sophisticated interconnected technology, interfacing the patient to
the healthcare practitioner thus expanding the reach and
availability of the Company’s services, beyond the traditional
clinic location, to geographic areas not readily providing
advanced, peripheral based healthcare services, including the
patient’s home.
- Third Pillar: Products. Develop and distribute effective,
personalized health and wellness product solutions allowing for the
customization of patient preventative care remedies and ultimately
a healthier population. The Company’s science-first approach to
product innovation further emphasizes our mandate to create and
provide over-the-counter preventative and maintenance care
solutions.
Innovation through science combined with the integration of
sophisticated, secure technology assures Novo Integrated Sciences
of continued cutting-edge advancement in patient first
platforms.
For more information concerning Novo Integrated Sciences, please
visit www.novointegrated.com. For more information on Novo
Healthnet Limited, Novo’s wholly owned subsidiary, please visit
www.novohealthnet.com
Twitter, LinkedIn, Facebook, Instagram, YouTube
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
included in this press release are forward-looking statements. In
some cases, forward-looking statements can be identified by words
such as "believe," “intend,” "expect," "anticipate," "plan,"
"potential," "continue" or similar expressions. Such
forward-looking statements include risks and uncertainties, and
there are important factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. These factors, risks and uncertainties
are discussed in Novo’s filings with the Securities and Exchange
Commission. Investors should not place any undue reliance on
forward-looking statements since they involve known and unknown,
uncertainties and other factors which are, in some cases, beyond
Novo’s control which could, and likely will, materially affect
actual results, levels of activity, performance or achievements.
Any forward-looking statement reflects Novo’s current views with
respect to future events and is subject to these and other risks,
uncertainties and assumptions relating to operations, results of
operations, growth strategy and liquidity. Novo assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. The contents of any website referenced in
this press release are not incorporated by reference herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220329005357/en/
Novo Integrated Sciences Chris David, COO-President
chris.david@novointegrated.com (888) 512-1195
Novo Integrated Sciences (NASDAQ:NVOS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novo Integrated Sciences (NASDAQ:NVOS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024